News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
486,587 Results
Type
Article (9394)
Company Profile (140)
Press Release (477052)
Multimedia
Podcasts (26)
Webinars (6)
Section
Business (167419)
Career Advice (316)
Deals (25819)
Drug Delivery (12)
Drug Development (53953)
Employer Resources (19)
FDA (9928)
Job Trends (8714)
News (239610)
Policy (18399)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (552)
Accelerated approval (26)
ADA (18)
Adcomms (6)
Allergies (96)
Alliances (33275)
ALS (106)
Alzheimer's disease (984)
Antibody-drug conjugate (ADC) (267)
Approvals (10475)
Artificial intelligence (331)
ASCO (168)
Autoimmune disease (208)
Automation (28)
Bankruptcy (264)
Best Places to Work (7035)
BIO (37)
Biologics (2)
BIOSECURE Act (1)
Biosimilars (109)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (30)
Breast cancer (509)
Cancer (3685)
Cardiovascular disease (223)
Career advice (252)
Career pathing (1)
CAR-T (175)
CDC (21)
Celiac Disease (1)
Cell therapy (494)
Cervical cancer (34)
Clinical research (48191)
Collaboration (1260)
Commercialization (3)
Compensation (1470)
Complete response letters (38)
COVID-19 (1472)
CRISPR (64)
C-suite (757)
Cystic fibrosis (90)
Data (5662)
Denatured (4)
Depression (103)
Dermatology (61)
Diabetes (344)
Diagnostics (4222)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (6)
Drug discovery (157)
Drug pricing (10)
Drug shortages (2)
Duchenne muscular dystrophy (171)
Earnings (73837)
Editorial (18)
Employer branding (3)
Employer resources (18)
Events (87710)
Executive appointments (708)
FDA (12549)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (936)
Gene editing (131)
Generative AI (12)
Gene therapy (335)
GLP-1 (309)
Government (1252)
Grass and pollen (2)
Guidances (281)
Healthcare (9488)
Hematology (95)
HIV (52)
Huntington's disease (24)
IgA nephropathy (66)
Immunology and inflammation (102)
Immuno-oncology (57)
Indications (157)
Infectious disease (1687)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (95)
Intellectual property (256)
Interviews (41)
IPO (12434)
IRA (3)
Job creations (2001)
Job search strategy (241)
JPM (4)
Kidney cancer (16)
Labor market (10)
Layoffs (82)
Leadership (1)
Legal (5241)
Licensing (8)
Liver cancer (44)
Longevity (17)
Lung cancer (512)
Lymphoma (250)
Machine learning (28)
Management (3)
Manufacturing (552)
Marketing (8)
MASH (119)
Medical device (8665)
Medtech (8810)
Mergers & acquisitions (14429)
Metabolic disorders (729)
mRNA (169)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (223)
Neuropsychiatric disorders (40)
Neuroscience (1840)
NextGen: Class of 2026 (3179)
Non-profit (850)
Now hiring (29)
Obesity (239)
Opinion (21)
Ovarian cancer (158)
Pain (173)
Pancreatic cancer (198)
Parkinson's disease (202)
Partnered (12)
Patents (489)
Patient recruitment (509)
Peanut (31)
People (41456)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15621)
Phase 2 (21544)
Phase 3 (14601)
Pipeline (7354)
Policy (47)
Postmarket research (1574)
Preclinical (6585)
Press Release (34)
Prostate cancer (190)
Psychedelics (14)
Radiopharmaceuticals (191)
Rare diseases (609)
Real estate (3047)
Recruiting (8)
Regulatory (15081)
Reports (21)
Research institute (652)
Resumes & cover letters (45)
Rett syndrome (41)
RNA editing (5)
RSV (68)
Schizophrenia (100)
Series A (158)
Series B (122)
Service/supplier (5)
Sickle cell disease (66)
Special edition (1)
Spinal muscular atrophy (88)
Sponsored (6)
Startups (2067)
Stomach cancer (3)
Supply chain (52)
Tariffs (4)
The Weekly (22)
Vaccines (674)
Venture capital (24)
Weight loss (83)
Women's health (79)
Date
Today (26)
Last 7 days (224)
Last 30 days (1660)
Last 365 days (19222)
2026 (12429)
2025 (19403)
2024 (23136)
2023 (26661)
2022 (34862)
2021 (37659)
2020 (33795)
2019 (23295)
2018 (17508)
2017 (18816)
2016 (17956)
2015 (24277)
2014 (21681)
2013 (18149)
2012 (20223)
2011 (20440)
2010 (20333)
Location
Africa (248)
Alabama (73)
Alaska (2)
Arizona (306)
Arkansas (11)
Asia (18026)
Australia (2108)
California (11988)
Canada (3149)
China (528)
Colorado (485)
Connecticut (409)
Delaware (208)
Europe (24938)
Florida (1790)
Georgia (380)
Hawaii (3)
Idaho (46)
Illinois (703)
India (51)
Indiana (319)
Iowa (15)
Japan (399)
Kansas (101)
Kentucky (30)
Louisiana (27)
Maine (26)
Maryland (1205)
Massachusetts (7896)
Michigan (307)
Minnesota (559)
Mississippi (4)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (116)
New Hampshire (60)
New Jersey (2633)
New Mexico (12)
New York (2837)
North Carolina (1282)
North Dakota (4)
Northern California (6002)
Ohio (279)
Oklahoma (14)
Oregon (16)
Pennsylvania (2266)
Puerto Rico (20)
Rhode Island (30)
South America (415)
South Carolina (76)
South Dakota (1)
Southern California (4971)
Tennessee (120)
Texas (1954)
United States (38966)
Utah (362)
Vermont (1)
Virginia (153)
Washington D.C. (41)
Washington State (929)
West Virginia (1)
Wisconsin (73)
Wyoming (1)
486,587 Results for "moderna inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Approvals
Moderna’s flu shot crosses FDA finish line, bouncing back from regulatory roadblock
The FDA in February slapped Moderna’s vaccine with a refusal-to-file letter—though the agency backtracked a few days later and accepted a revised submission for review. An advisory committee in June unanimously backed mFLUVISA’s approval.
August 6, 2026
·
2 min read
·
Tristan Manalac
Earnings
Moderna maintains 10% growth target despite Phase 3 norovirus miss
Moderna’s norovirus vaccine failed in a Phase 3 trial, but the company still has faith in an ambitious revenue growth target thanks to ex-U.S. vaccine sales and a unanimous FDA adcomm win for mFLUSIVA.
July 31, 2026
·
4 min read
·
Gabrielle Masson
Adcomms
Moderna’s mRNA flu shot wins unanimous support at FDA adcomm in rebuke of former leadership
The FDA in February briefly refused to review Moderna’s flu vaccine, citing trial inadequacies, but reversed course a few days later. A verdict is expected by Aug. 5.
June 19, 2026
·
2 min read
·
Tristan Manalac
mRNA
ASCO: Moderna’s mRNA-based melanoma vaccine shows ‘encouraging’ 5-year survival
When used alongside Merck’s Keytruda, Moderna’s personalized cancer vaccine halved the risk of death or disease recurrence in a mid-stage trial of advanced melanoma—a result analysts said could help “instill confidence” in the regimen.
June 2, 2026
·
2 min read
·
Tristan Manalac
Adcomms
Moderna’s once-rebuffed mRNA flu shot to face scrutiny from FDA adcomm
After getting slapped with a surprise refuse-to-file letter signed by former CBER Director Vinay Prasad, Moderna’s flu vaccine application will now go before the FDA’s Vaccine advisory committee.
May 22, 2026
·
2 min read
·
Tristan Manalac
Podcast
Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more
Moderna appears to have aligned with the FDA ahead of an advisory committee meeting for its mRNA-based flu vaccine, which the regulator initially turned away in February; biotech IPOs are going gangbusters, including two new records raises in as many weeks; layoffs continue across biopharma; plus much more.
June 17, 2026
·
2 min read
·
Jef Akst
Cancer
Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal
Melanoma was slower to recur in patients receiving Merck and Moderna’s mRNA vaccine with Keytruda, supporting use of the combination in adjuvant treatment. The partners plan to take the data to the FDA.
August 19, 2026
·
3 min read
·
Nick Paul Taylor
Vaccines
FDA, Moderna appear aligned on mRNA flu shot heading into adcomm
The Vaccines and Related Biological Products Advisory Committee will meet June 18 to discuss Moderna’s seasonal flu vaccine mRNA-1010 after the FDA initially refused to accept the application in February.
June 16, 2026
·
3 min read
·
Annalee Armstrong
Vaccines
Moderna’s stock rides hantavirus fears as spotlight returns to infectious disease platform
While the pathogen appears unlikely to trigger a pandemic, analysts see potential for Moderna to build goodwill amid a period of political pressure on vaccine manufacturers.
May 20, 2026
·
4 min read
·
Nick Paul Taylor
Press Releases
Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna’s Investigational Vaccine Against Bundibugyo Ebolavirus
August 4, 2026
·
5 min read
1 of 48,659
Next
